^
    11ms
    A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=110, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    ZG19018
    over1year
    First-in-human study of ZG19018, targeting KRAS G12C, as monotherapy in patients with advanced solid tumors. (ASCO 2023)
    ZG19018 is tolerable and demonstrates a good safety under the dose level of 450 mg bid. It also demonstrates preliminary antitumor effects in pts with solid tumors, with reasonable PK profiles. Clinical trial information: ChiCTR20220296.
    Clinical • P1 data • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    ZG19018
    almost2years
    Preclinical studies of ZG19018, a novel irreversible covalent inhibitor of KRAS G12C, for the treatment of advanced non-small cell lung cancer and other solid tumors (AACR 2023)
    Growing evidences of covalent irreversible inhibitors in clinical treatments of solid tumors with KRAS G12C mutation have recently emerged after FDA-approved AMG510 (Sotorasib) for NSCLC chemotherapies. The genotoxic potential studies indicated ZG19018 without mutagenesis. Collectively, ZG19018 is now in phase I/II clinical trials for the treatments of solid tumors with KRAS G12C mutation in China.
    Preclinical • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C
    |
    Lumakras (sotorasib) • ZG19018